Zum Hauptinhalt springen


Zuletzt bearbeitet: Zuletzt revidiert:
Zuletzt revidiert von:

  1. Richmond EJ, Rogol AD. The child with tall stature and/or abnormally rapid growth. UpToDate, last updated Sep 05, 2014. UpToDate  
  2. Barstow C, Rerucha C. Evaluation of short and tall stature in children. Am Fam Physician 2015 Jul 1; 92(1): 43-50. pmid: 26132126 PubMed  
  3. Tanner JM, Whitehouse RH, Takaishi M. Clinical longitudinal standards for height, weight, height velocity, weight velocity and stages of puberty. Arch Dis Child 1976; 51: 170. PubMed  
  4. Healy MJ, Lockhart RD, Mackenzie JD, et al. Aberdeen growth study. I. The prediction of adult body measurements from measurements taken each year from birth to 5 years. Arch Dis Child 1956; 31: 372. PubMed  
  5. Barnes-Powell LL. Infants of diabetic mothers: the effects of hyperglycemia on the fetus and neonate. Neonatal Netw 2007; 26: 283. PubMed  
  6. Agwu JC, Shaw NJ, Kirk J, et al. Growth in Sotos syndrome. Arch Dis Child 1999; 80: 339. PubMed  
  7. Weng EY, Moeschler JB, Graham JM Jr. Longitudinal observations on 15 children with Wiedemann-Beckwith syndrome. Am J Med Genet 1995; 56: 366. PubMed  
  8. Joss EE, Temperli R, Mullis PE. Adult height in constitutionally tall stature: accuracy of five different height prediction methods. Arch Dis Child 1992; 67: 1357. PubMed  
  9. Biro FM, Khoury P, Morrison JA. Influence of obesity on timing of puberty. Int J Androl 2006; 29: 272. PubMed  
  10. Bardsley MZ, Kowal K, Levy C, et al. 47,XYY syndrome: clinical phenotype and timing of ascertainment. J Pediatr 2013; 163:1085. PubMed  
  11. Chung TT, Chan LF, Metherell LA, Clark AJ. Phenotypic characteristics of familial glucocorticoid deficiency (FGD) type 1 and 2. Clin Endocrinol (Oxf) 2010; 72:589. PubMed  
  12. Malchoff CD, Javier EC, Malchoff DM, et al. Primary cortisol resistance presenting as isosexual precocity. J Clin Endocrinol Metab 1990; 70: 503. PubMed  
  13. Garg A, Agarwal AK. Lipodystrophies: disorders of adipose tissue biology. Biochim Biophys Acta 2009; 1791:507. PubMed  
  14. Rayner JA, Pyett P, Astbury J. The medicalisation of 'tall' girls: A discourse analysis of medical literature on the use of synthetic oestrogen to reduce female height. Soc Sci Med 2010; 71:1076. PubMed  
  15. Barnard ND, Scialli AR, Bobela S. The current use of estrogens for growth-suppressant therapy in adolescent girls. J Pediatr Adolesc Gynecol 2002; 15: 23-26. PubMed  
  16. Venn A, Bruinsma F, Werther G, et al. Oestrogen treatment to reduce the adult height of tall girls: long-term effects on fertility. Lancet 2004; 364: 1513-8. PubMed  
  • Terje Johannessen, professor i allmennmedisin, Institutt for samfunnsmedisinske fag, Norges teknisk-naturvitenskapelige universitet, Trondheim
  • Otto Westphal, docent och överläkare, Centrum för pediatrisk tillväxtforskning, Sahlgrenska akademin, Göteborgs universitet (Medibas)
  • John Cooper, spesialist i allmennmedisin og indremedisin, Medisinsk avdeling, Sentralsjukehuset i Rogaland, Stavanger
  • Stein Vaaler, overlege dr. med., Senter for Klinisk Epidemiologi, Rikshospitalet, Universitetet i Oslo